Navigation Links
GenoSpace Expands Its Management Team by Appointing Daniel Meyer as Chief Financial Officer
Date:3/28/2013

CAMBRIDGE, Mass., March 28, 2013 /PRNewswire/ -- GenoSpace, LLC, a company that builds information systems capable of storing and integrating genomic information and other health data for clinical care and advanced research, today announced the addition of Daniel Meyer as Chief Financial Officer.

(Logo: http://photos.prnewswire.com/prnh/20130328/NE84802LOGO)

"We have been working with Dan in an advisory relationship since forming the company, and are pleased to be able to bring him on full time," stated John Quackenbush , PhD., CEO of GenoSpace. "The GenoSpace team has produced incredible successes since we launched and we are getting excellent feedback from our customers and users at clinical labs and research institutions. Our ability to build the senior management team reflects the rapidly growing scale of our business and quality of our pipeline."

Mr. Meyer has spent his entire career in life sciences entrepreneurship, venture capital and investment banking. He covered the healthcare portfolios at Arboretum Ventures and Point Judith Capital, where he focused on investments in life science tools, medical devices, healthcare information technology and services. Prior to his work investing in early stage companies, Mr. Meyer was a member of the health care investment banking team at Credit Suisse First Boston. He was also a co-founder and the General Manager of a medical device startup from inception through prototype development. Mr. Meyer holds a B.A. in Mathematics and Economics from Middlebury College and an M.B.A. from the Tuck School of Business at Dartmouth.

About GenoSpace
At GenoSpace, we are Digital Architects of Genomic Medicine™. GenoSpace is a Cambridge, Massachusetts-based company that has developed robust software systems for securely storing vast amounts of genomic and health data, and providing it in formats specific to its diverse user communities. GenoSpace for Clinical Care™ facilitates clinically actionable interpretation and report generation for precision medicine. GenoSpace for Research™ provides dynamic analysis, visualization and collaboration tools. GenoSpace for Patient Communities™ enables patient-centric exploration and advancement of personalized medicine.

GenoSpace has created an information ecosystem for 21st century genomic medicine—one that enables different participants in precision medicine to realize the potential of our ever-expanding knowledge of human disease and its treatment. Please visit www.GenoSpace.com for more information.

Company Contact:
John Quackenbush
Chief Executive Officer
GenoSpace, LLC
info@genospace.com


'/>"/>
SOURCE GenoSpace, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine
2. GLM Displays Expands Its Line of Formulate Fabric Displays with the Vibe 10ft Display
3. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
4. Leading Chemical Manufacturer Expands Biobased Offering through Unique Distribution of Proven Green Spill Absorbent
5. Defying Industry Trends, BBK Worldwide Expands Ownership From Within
6. Abacus International Expands Annual Partnership With HealthEconomics.Com
7. Personal Genome Diagnostics Inc. Licenses Genome-Mapping Technology from Johns Hopkins University and Expands Its Cancer Genome Analysis Business
8. Delta Point Strengthens Management and Expands Consultancy Services with Addition of Former AstraZeneca Executive Michael Hickey
9. SAFC Expands Irvine Facility to Add Dry Powder Media Manufacturing Capabilities
10. Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
11. XBiotech Expands Portfolio to Include Biosimilars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... Mitotech S.A, a Luxembourg based clinical ... Neuropathy (LHON) patients. LHON is a rare devastating genetic disease that leads to a ... in a group of 20 patients carrying 11778, 14484 and 3460 mutations and having ...
(Date:4/27/2017)... ... April 27, 2017 , ... Sierra Instruments announces ... capillary thermal mass flow technology provide exponentially more accurate mass flow data than ... of all industrial processes—such as those involving chemical reactions, combustion, respiration, pharmaceutical, and ...
(Date:4/27/2017)... April 27, 2017  Pendant Biosciences, Inc. (formerly Nanoferix, ... modification and drug delivery technologies, today announced that it ... @ Toronto . ... Pendant Biosciences, noted, "We are excited to become part ... community, and are honored to be the first ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... for phase I clinical trials comes to Tampa, San Francisco and Boston in ... professionals representing FDA regulated organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
Breaking Biology News(10 mins):